Statin therapy improves outcomes after valvular heart surgery

Area of Science:

• Cardiology
• Pharmacology

Background:

• 3-hydroxy-3-methylglutaryl coenzyme A (HMG Co-A) reductase inhibitors (statins) are known to benefit patients undergoing coronary artery bypass grafting.
• The impact of statin therapy on outcomes in patients undergoing cardiac valve operations was investigated.

Purpose of the Study:

• To evaluate the association between statin use and postoperative outcomes in patients undergoing cardiac valve surgery.
• To compare morbidity and mortality rates between patients who received statins and those who did not.

Main Methods:

• A retrospective study of 447 consecutive patients undergoing valve operations between July 2004 and February 2006.
• Comparison of preoperative risk factors and outcome data between 203 patients on statins and 244 patients not on statins.
• Primary outcomes assessed included 30-day mortality, renal failure, and postoperative stroke.

Main Results:

• The statin group, despite having more comorbidities and risk factors (e.g., diabetes, previous stroke, dyslipidemia), demonstrated better outcomes.
• Unadjusted analysis showed a trend favoring the statin group for the composite endpoint of death/stroke/renal failure (OR 1.90, p=0.068).
• Adjusted univariate analysis revealed a significant benefit of statin therapy for the composite endpoint (e.g., diabetes OR 2.29, p=0.024; stroke OR 2.15, p=0.034).

Conclusions:

• Statin therapy in patients undergoing cardiac valve procedures is associated with reduced postoperative morbidity and mortality.
• The beneficial mechanism of statins in this context may be independent of their lipid-lowering effects.
• Further investigation via a prospective, randomized-controlled trial is recommended to confirm these findings.